Flex Pharma Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Flex Pharma (FLKS) PT Lowered to $8 at Jefferies; HotShot Sales Impacted by Seasonality
May 4, 2017 8:19 AM EDTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $8.00 (from $9.00) while maintaining a Buy rating.
Analyst Matthew Andrews notes HotShot sales were affected by seasonality as expected though there are signals that Q2 is off to a good start.
The firm cut FY 2017 EPS from ($1.90) to ($2.13)
... More